There are many reports about causes of corrosive agents such as acids and alkaline and occasionally hot food in either liquid or solid forms as causes of upper gastrointestinal mucosal injury. However, there have been no reports on bowel preparation solutions as a cause of upper gastrointestinal injury. We describe a case of bowel preparation solution (PICOLIGHT powder) induced thermal injury of the gastric mucosa with a review of the literature.
Cathartics ; Gastric Mucosa*

Gastritis cystica polyposa (GCP) is a rare lesion characterized by hyperplastic and cystic dilatation of the gastric mucous glands infiltrating into the underlying submucosa. A cumulative experience suggests that GCP represents a manifestation of a spectrum of reactive inflammatory responses to mucosal injury. The case reported herein is a GCP developed as multiple polypoid lesions with a circular arrangement in the gastric mucosae along the gastrojejunostomy site.
Dilatation ; Gastric Bypass ; Gastric Mucosa ; Gastritis*

Heterotopia refers to the finding of normal tissue in foreign sites, entirely separate from the main organ. Heterotopic gastric mucosa has been observed throughout the alimentary tract, everywhere from the oral cavity to the rectum. However, occurrences in the umbilicus are an extremely rare and peculiar phenomena. We report the case of heterotopic gastric mucosa in the umbilicus.
Gastric Mucosa ; Mouth ; Rectum ; Umbilicus

The study was conduced on 528 patients aged > 19 years old with chronic gastritis (346 males and 182 females). Among plasia, 58 cases of dysplasia. Results showed a higher rate of intestinal heteroplasia, dysplasial, Helicobacter pylori infection in the group of atrophic inflamatory. The incidence of HP infection was higher, the incidence of active gastritis was severer. the more severe atrophic inflammation, the higher incidence of intestinal heteroplasia and dysplasia was. The higher intestinal heteroplasia and dysplasia, the larger HP infection was. HP infection in stomach mucous increased the risk of intestinal heteroplasia and dysplasia in patients with chronic gastritis.
Diagnosis ; Helicobacter pylori ; Gastric Mucosa

No abstract available.
Gastric Mucosa* ; Meckel Diverticulum* ; Ulcer*

No abstract available.
Gastric Mucosa* ; Helicobacter pylori* ; Helicobacter*

18 cases with pepsic ulceration and infected H.pylory received omeprazole, amoxicilline and metronidazole (OAM) in a week and treated complementarily with trymo in 4 weeks. The results of treatment were evaluated by histology; ultrasound and endoscopy have shown that pain relief: 94.4%, ulcerative healing: 88.9%, eradication of H.pylori: 77.8%; the rate of ulcerative healing and eradication of H.pylori: 94.4% reduction of inflamatory express: after 6 months and 12 months of treatment: 72.2 and 77.8% respectively.
Peptic Ulcer ; Gastric Mucosa ; therapeutics

The radiologic findings of prolapsed gastric mucosa through gastrojejunostomy stoma after gastrectomy is very characteristic, but recurrent gastric cancer, retrograde jejunogastric intussusception, and Hofmeister defect should be differentiated from it because of their simillar postoperative upper gastrointestinal series findings.The author reports 3 cases of prolapsed gastric mucosa through gastrojejunostomy stoma after Hofmeister's gastrectomy with brief review of the literature.
Gastrectomy ; Gastric Bypass ; Gastric Mucosa ; Intussusception ; Stomach Neoplasms

BACKGROUND/AIMS: Phase IIb clinical study of Stillen(TM), a novel cytoprotectant, for gastritis showed 180 mg of Stillen, t.i.d. for 2 weeks results in a significant increase of cure rate when compared with a placebo group. It is reported that antioxidative effect and strengthening the endogenous cytoprotective molecules of the gastric mucosa play a pivotal role for cytoprotective action of Stillen(TM). The aim of this phase III multicenter, double-blind comparative study was to assess the efficacy of Stillen(TM) for the treatment of erosive gastritis. METHODS: Five hundred and twelve patients with erosive gastritis were enrolled and divided into three groups. Each group received 180 mg or 360 mg of Stillen(TM) or 600 mg of cetraxate (Neuer(TM)) t.i.d. for 2 weeks, respectively and a follow-up endoscopic examination for evaluation. RESULTS: Patients treated with 180 mg and 360 mg of Stillen(TM) had a significantly improved endoscopic cure rate of gastritis (55.6% and 57.5%, respectively) compared with patients treated with 600 mg of cetraxate (35.5%, p<0.001). Endoscopic improvement rate was also significantly higher in 180 mg group (67.3%) and 360 mg group (65.0%) of Stillen(TM) treated patients than cetraxate treated group (46.4%, p<0.001). During the study, both Stillen(TM) and cetraxate were well tolerated. CONCLUSIONS: These results clearly demonstrate that Stillen(TM) is an efficacious, safe, and well-tolerated treatment for gastritis.
Follow-Up Studies ; Gastric Mucosa ; Gastritis* ; Humans

No abstract available.
Eating* ; Gastric Mucosa* ; Hydrochloric Acid* ; Mucous Membrane*